Kymera Therapeutics, Inc. (KYMR) Form 8-K — Oct 29, 2026
Kymera Therapeutics reported third quarter 2026 results with a net loss of $132.0 million, wider than $82.2 million a year ago, driven by R&D spending that jumped to $128.5 million from $74.1 million on STAT6 program and platform investment. The headline positive was Phase 1 data for KT-579, an oral IRF5 degrader, which showed ≥90% sustained IRF5 degradation, robust suppression of inflammatory cytokines (88% TNFα, 94% IL-1β, 98% IFNβ inhibition at Day 14), and a placebo-comparable safety profile. A LUMORA Phase 1b trial in lupus patients is planned by early 2027.
Key figures
- Revenue
- 0
- Guidance
- KT-621 BROADEN2 Phase 2b AD topline data by year-end 2026; first Phase 3 AD trial by mid-2027; KT-621 BREADTH asthma topline data late 2027; KT-579 LUMORA Phase 1b lupus trial to start by early 2027; no additional collaboration revenue expected in 2026; cash runway into 2029
- Total Assets
- 1767269000
- Cash Position
- 1645883000
- Prior year q3 net loss
- $82.2M
- Q3 2026 g and a expense
- $18.7M (vs $17.3M Q3 2025)
- Q3 2026 r and d expense
- $128.5M (vs $74.1M Q3 2025)
- Weighted avg shares q3 2026
- 100097242
- Kt579 cytokine inhibition day14
- 88% TNFα, 87% IL-12/23p40, 94% IL-1β, 98% IFNβ
- Kt579 mad median irf5 degradation
- ≥90% across multiple dose levels
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.